Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UX-DA002 is an investigational allogeneic cell therapy under development by UniXell Biotechnology. While detailed public information on the specific cell type, mechanism of action, or target indication for UX-DA002 is not yet available, it is described as a next-generation product following UX-DA001. Unlike the autologous iPSC-derived neural progenitor cell therapy (UX-DA001) for Parkinson’s disease, which uses a patient’s own cells, UX-DA002 utilizes donor-derived cells (allogeneic), potentially enabling off-the-shelf availability and broader clinical application. The drug has attracted regulatory interest and represents UniXell Biotechnology's continued efforts in innovative cell therapies[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UX-DA002.